UCB:EBR
UCB SA
€204,60
arrow_downward
-0,68%(-1,40) 1D
16 ຕ.ລ., 17 ໂມງ 37 ນາທີ 21 ວິນາທີ GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for UCB...
Open
€204,50
High
€205,10
Low
€201,30
Mkt. cap
39,39 ຕື້
Avg. vol.
248,57 ພັນ
Volume
324,45 ພັນ
Dividend
0,50%
Quarterly dividend
€0,25
Ex-dividend date
4 ພ.ພ. 2026
P/E ratio
18,09
52-wk high
€289,50
52-wk low
€197,45
EPS
€11,31
Shares outstanding
194,51 ລ້ານ
No. of employees
9 ພັນ
Open
€204,50
High
€205,10
Low
€201,30
Mkt. cap
39,39 ຕື້
Avg. vol.
248,57 ພັນ
Volume
324,45 ພັນ
Dividend
0,50%
Quarterly dividend
€0,25
Ex-dividend date
4 ພ.ພ. 2026
P/E ratio
18,09
52-wk high
€289,50
52-wk low
€197,45
EPS
€11,31
Shares outstanding
194,51 ລ້ານ
No. of employees
9 ພັນ
News stories
From web sources and news partners
ad-hoc-news.de
·
19 ຊົ່ວໂມງກ່ອນ
UCB launches Wear It Out: what it means for UCB stock
Profile
UCB is a multinational biopharmaceutical company headquartered in Brussels, Belgium. UCB is an international company with revenue of €4.178 billion in 2016 which focuses primarily on research and development, specifically involving medications centered on epilepsy, Parkinson's disease, and Crohn's disease. The company's efforts are focused on treatments for severe diseases treated by specialists, particularly in the fields of central nervous system disorders, inflammatory disorders, and oncology.
Every three years, the company presents the UCB Award under the patronage of the Queen Elisabeth Medical Foundation to promote neuroscience research. The winner of this award is selected by an independent scientific committee. Wikipedia
About UCB SA
CEOJean-Christophe Tellier
Employees9 ພັນ
Founded18 ມ.ກ. 1928
Headquarters-
SectorPharmaceutical industry
Websiteucb.com